ACM
CSTL icon

AIGH Capital Management’s Castle Biosciences CSTL Stock Holding History

AIGH Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13M Sell
545,101
-45,500
-8% -$1.01M 0.82% 22
2026
Q1 		$14.5M Sell
590,601
-34,118
-5% -$1.12M 1.98% 13
2025
Q4 		$24.3M Sell
624,719
-82,568
-12% -$2.66M 5.88% 3
2025
Q3 		$16.1M Buy
+707,287
New +$14.4M 4.54% 8

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AIGH Capital Management's CSTL Position: Q2 2026 in Review

AIGH Capital Management reduced its Castle Biosciences (CSTL) stake by 7.7% in Q2 2026, selling an estimated $1.01M and leaving 545,101 shares worth $13M. The position accounts for 0.82% of the portfolio, ranked #22.

AIGH Capital Management first reported a position in CSTL in Q3 2025 and has held it in 4 quarters since. The position peaked at $24.3M in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • AIGH Capital Management held 545,101 shares of Castle Biosciences worth $13M as of Q2 2026.
  • AIGH Capital Management sold 45,500 Castle Biosciences shares in Q2 2026, an estimated $1.01M.
  • Castle Biosciences made up 0.82% of AIGH Capital Management's portfolio in Q2 2026, its #22 holding.
  • AIGH Capital Management first reported a position in Castle Biosciences in Q3 2025 and has held it in 4 quarters since.
  • AIGH Capital Management's Castle Biosciences position peaked at $24.3M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on AIGH Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.